Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
Hida T, Nishio M, Nogami N, Ohe Y, Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H, Fujita S, Tanaka H, Minato K, Takahashi T, Maemondo M, Takeda K, Saka H, Goto K, Atagi S, Hirashima T, Sumiyoshi N, Tamura T. Hida T, et al. Among authors: hirashima t. Cancer Sci. 2017 May;108(5):1000-1006. doi: 10.1111/cas.13225. Epub 2017 Apr 26. Cancer Sci. 2017. PMID: 28266091 Free PMC article. Clinical Trial.
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Hida T, Tamiya M, Nishio M, Yamamoto N, Hirashima T, Horai T, Tanii H, Shi MM, Kobayashi K, Horio Y. Hida T, et al. Among authors: hirashima t. Cancer Sci. 2011 Apr;102(4):845-51. doi: 10.1111/j.1349-7006.2010.01839.x. Epub 2011 Feb 8. Cancer Sci. 2011. PMID: 21205086 Free article. Clinical Trial.
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.
Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T. Okamoto I, et al. Among authors: hirashima t. Invest New Drugs. 2013 Oct;31(5):1275-82. doi: 10.1007/s10637-013-9941-z. Epub 2013 Mar 10. Invest New Drugs. 2013. PMID: 23475281 Clinical Trial.
Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K. Kogure Y, et al. Among authors: hirashima t. J Thorac Oncol. 2013 Jun;8(6):753-8. doi: 10.1097/JTO.0b013e31828b51f5. J Thorac Oncol. 2013. PMID: 23575412 Free article.
A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M, Tamiya A, Kaneda H, Nakagawa K, Yoh K, Goto K, Okamoto H, Shimokawa T, Abe T, Tanaka H, Daga H, Takeda K, Hirashima T, Atagi S. Tamiya M, et al. Among authors: hirashima t. Med Oncol. 2016 Jan;33(1):2. doi: 10.1007/s12032-015-0715-7. Epub 2015 Nov 24. Med Oncol. 2016. PMID: 26603297 Clinical Trial.
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I. Takeda M, et al. Among authors: hirashima t. Cancer. 2016 Apr 1;122(7):1050-9. doi: 10.1002/cncr.29893. Epub 2016 Feb 1. Cancer. 2016. PMID: 26828788 Free article. Clinical Trial.
Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.
Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T, Nogami N, Saka H, Takenoyama M, Maemondo M, Ohe Y, Nokihara H, Hirashima T, Tanaka H, Fujita S, Takeda K, Goto K, Satouchi M, Isobe H, Minato K, Sumiyoshi N, Tamura T. Nishio M, et al. Among authors: hirashima t. ESMO Open. 2017 Mar 7;1(4):e000108. doi: 10.1136/esmoopen-2016-000108. eCollection 2016. ESMO Open. 2017. PMID: 28861280 Free PMC article.
Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T. Shiroyama T, et al. Among authors: hirashima t. Cancer Med. 2018 Jan;7(1):13-20. doi: 10.1002/cam4.1234. Epub 2017 Nov 18. Cancer Med. 2018. PMID: 29150906 Free PMC article.
391 results